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Abstract
Background: Screening invitations have traditionally been brief, providing information only about
population benefits. Presenting information about the limited individual benefits and potential
harms of screening to inform choice may reduce attendance, particularly in the more socially
deprived. At the same time, amongst those who attend, it might increase motivation to change
behavior to reduce risks. This trial assesses the impact on attendance and motivation to change
behavior of an invitation that facilitates informed choices about participating in diabetes screening
in general practice. Three hypotheses are tested:
1. Attendance at screening for diabetes is lower following an informed choice compared with a
standard invitation.
2. There is an interaction between the type of invitation and social deprivation: attendance
following an informed choice compared with a standard invitation is lower in those who are more
rather than less socially deprived.
3. Amongst those who attend for screening, intentions to change behavior to reduce risks of
complications in those subsequently diagnosed with diabetes are stronger following an informed
choice invitation compared with a standard invitation.
Method/Design: 1500 people aged 40–69 years without known diabetes but at high risk are
identified from four general practice registers in the east of England. 1200 participants are
randomized by households to receive one of two invitations to attend for diabetes screening at
their general practices. The intervention invitation is designed to facilitate informed choices, and
comprises detailed information and a decision aid. A comparison invitation is based on those
currently in use. Screening involves a finger-prick blood glucose test. The primary outcome is
attendance for diabetes screening. The secondary outcome is intention to change health related
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BMC Public Health 2009, 9:63 http://www.biomedcentral.com/1471-2458/9/63behaviors in those attenders diagnosed with diabetes. A sample size of 1200 ensures 90% power
to detect a 10% difference in attendance between arms, and in an estimated 780 attenders, 80%
power to detect a 0.2 sd difference in intention between arms.
Discussion: The DICISION trial is a rigorous pragmatic denominator based clinical trial of an
informed choice invitation to diabetes screening, which addresses some key limitations of previous
trials.
Trial registration: Current Controlled Trials ISRCTN73125647
Background
Invitations to attend for screening traditionally provide
information about its population benefits and aim to
achieve high rates of uptake [1]. They do not usually refer to
the likelihood of health benefits for the individual, which are
low [2], nor to the possibility of adverse effects. This neglect
reflects a greater concern with potential public health bene-
fits than with individual autonomy. There has, however,
been a policy change in the UK and elsewhere [3,4] towards
a view that participation in screening programmes should
reflect individual choices informed about both the nature
and frequency of possible individual benefits and harms of
screening. Invitations to participate in screening do not rou-
tinely reflect this policy change. This may reflect a reluctance
of those organizing screening programmes to implement a
policy change that may privilege concern for informed
choice to the neglect of achieving the public health benefits
of screening [5]. Giving information about the type and fre-
quencies of individual benefits and burdens could deter
some people from participating in screening programmes [6-
9]. We therefore test the hypothesis that facilitating informed
choice results in lower screening attendance than when
informed choices are not facilitated.
A further concern is that invitations that support informed
choice may reduce uptake differentially across social groups
resulting in lower uptake amongst the more socially
deprived. These groups are also likely to be those in poorest
health and hence those in whom the benefits of screening
might be greatest [10]. Given that participation in screening
programmes is already lower in these groups [11], an
informed choice policy could increase the health gap
between socially more and less advantaged groups in one
of two ways. Information on the limitations of screening
may have greater impact upon the more socially deprived
because they are less aware of such limitations [12-14].
Information about the possible longer term benefits and
more immediate harms of screening may also be more
demotivating among this group which is known to be ori-
ented more towards the present than to the future, both
generally and in relation to their health [15,16]. Indeed,
one of the few studies to examine the impact of risk infor-
mation across social groups found that a risk counseling
intervention designed to increase attendance for mammog-
raphy had no impact on those with high levels of education
but decreased attendance in those with lower levels [17].
Consequently, we predict that an informed choice invita-
tion will differentially affect attendance among individuals
who are more socially deprived compared with those who
are less socially deprived.
Informed choice invitations attempt to enhance individual
autonomy. This may lead to increased motivation to reduce
identified risk among those accepting the invitation for
screening [18-22]. According to Self Determination Theory
[22] autonomous decisions are more intrinsically motivated;
that is, the individual has greater personal interest in the
behavior, thus the decision is more likely to lead to action
[23]. In the case of diabetes, the most effective way of reduc-
ing risk is by changing behavior (improving diet, increasing
physical activity, taking medication) [24,25]. Therefore, we
predict stronger intentions to engage in these risk reducing
behaviors in those attending for diabetes screening after
receiving an informed choice invitation than in those who
received a standard invitation.
The ethical dilemma central to the proposed research con-
cerns the potential conflict between two fundamental
moral principles guiding health care practice and policy:
on the one hand, patient-centered practice, which privi-
leges the principle of respect for individual autonomy;
and on the other, the promotion of public health benefits,
which privileges achieving the greatest overall benefit. The
current trial examines whether such an ethical conflict fol-
lows the implementation of an informed choice policy in
the context of screening.
Achieving informed choices in screening
Informed choices or decisions can be considered to have
two theoretical core characteristics: first, they should be
informed by best current evidence; and second, they
should reflect the decision-maker's values [26,27]. In
making an informed choice people are neither deceived
nor coerced [28]. Individuals first need good quality infor-
mation that can be read and understood across a wide
range of literacy as a necessary, although not sufficient,
basis for an informed choice.
Decision aids aimed at conveying written information
and structuring the decision-making process can be usedPage 2 of 12
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interventions including screening. The few published
evaluations of self-administered decision aids provide
some evidence that knowing about and evaluating the
personal importance of the benefits and risks associated
with a particular choice can help individuals to clarify
their values. This improves the quality of their subsequent
decisions [29]. Thus, for example, the use of a decision aid
supporting women's decisions to use hormone replace-
ment therapy resulted in more accurate perceptions of
breast cancer risks, greater confidence to make a decision
and more satisfaction with the decision made [30]. How-
ever, the evidence is limited and mixed. Four of the 10
studies reviewed by O'Connor and colleagues [29] found
significant improvements in decision quality, as meas-
ured by the decisional conflict scale [31]; the remaining
six studies found no significant effects of a decision aid in
improving the decision making process.
The impact of decision aids on screening uptake has also
been mixed and small. Krist, Woolf, Johnson, & Kerns
[32] found requests for prostate cancer screening tests
were lower in those using a decision aid, whereas Mathieu
and colleagues [33] reported no difference in breast can-
cer screening uptake in women using a decision aid com-
pared to those not using the aid. Similarly, Trevena, Irwig,
& Barratt [34] found no impact of a decision aid on rates
of self reported use of colorectal screening kits.
Differences in findings between studies may relate to the
characteristics of the groups invited, the nature of the invi-
tation or decision aid, the precision and invasiveness of
the test, the prevalence, severity and treatability of the dis-
ease screened for, or the rigor of the study designs and
measures used to evaluate screening interventions. Trials
of informed choice in screening may be particularly vul-
nerable to methodological bias. Traditionally, screening
has been promoted by health professionals, so self report
measures of screening attendance might be inaccurate.
Furthermore, the consent process might select partici-
pants who are more likely to attend for screening [35]. For
example, people refusing consent to participate in a
screening trial may do so because they have no intention
of attending for screening. In a trial of colorectal cancer
screening, over 75% of general practice patients contacted
chose not to consent to take part in the trial [34]. By con-
trast Krist and colleagues [32] recruited men to a prostate
cancer trial taking place during a health examination that
the men had already scheduled. Only 5% did not consent.
In addition, there is evidence that questionnaires can alter
research outcomes [36-38]; baseline questionnaires may
prompt greater reflection on aspects of screening covered
in the measures, thereby altering responses.
Given the uncertain effect of attempts to support informed
choice and to evaluate its effects on screening uptake we
have designed a rigorous pragmatic, population based ran-
domized trial evaluating the effect on uptake of screening
for type 2 diabetes of a validated invitation designed to
inform the choice to attend. This trial protocol is designed
to measure real screening decisions, in a primary care set-
ting, unbiased by prior consent to study participation. This
is the first trial of an informed choice decision aid for
screening which includes all these design features.
Screening for type 2 diabetes
Screening for type 2 diabetes and cardiovascular risk was
chosen for study as type 2 diabetes is a condition for
which behavior change (increasing physical activity,
improving diet adherence to medication) is a major com-
ponent of treatment [25], and for which at-risk popula-
tion-based screening programmes are now being
proposed and implemented [39-41]. Type 2 diabetes is a
serious condition that is commonly undiagnosed until
complications occur [42,43]. Existing evidence suggests
that the adverse consequences of screening are likely to be
limited [44,45] and that intensive treatment of clinically
diagnosed patients is beneficial [24].
Uncertainties remain in relation to the overall cost-effec-
tiveness of detection by screening and initiation of treat-
ment earlier in the trajectory of the disease [43]. Evidence
suggests that screening individuals at high risk of undiag-
nosed diabetes is most cost-effective [43,46], and that pre-
venting complications arising from diabetes through
behavior change in individuals in the early stages of the
disease is more effective than treatments for those compli-
cations [47,48]. Patients at higher risk of undiagnosed
diabetes can be identified using the Cambridge Risk Score
[42,49-51], which can be used to select patients to invite
for diabetes screening and to explore the impact of risk of
undiagnosed diabetes on lifestyle choices.
Study objective
The study objective is to estimate the impact upon attend-
ance for diabetes screening of an informed choice invita-
tion compared with a standard invitation. This is
examined both overall and stratified by social depriva-
tion. A secondary objective is to describe, amongst attend-
ers, intention to change health-related behaviors if
diabetes were subsequently detected. Intentions amongst
attenders receiving the informed choice and standard invi-
tations are compared.
The trial tests three principal hypotheses:
1. Attendance at screening for diabetes is lower following
an informed choice compared with a standard invitation
2. There is an interaction between the type of invitation
and social deprivation: attendance following an informedPage 3 of 12
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those who are more rather than less socially deprived.
3. Amongst those who attend for screening, intentions to
change behavior to reduce risks of complications in those
subsequently diagnosed with diabetes are stronger follow-




The study design and participant recruitment (completed
July 2007) is shown in figure 1. DICISION is a rand-
omized controlled trial testing the impact of an invitation
designed to facilitate informed choice (referred to as the
informed choice invitation) on attendance for type 2 dia-
betes screening. The group that receives the informed
choice invitation is compared to a group that receives an
invitation typical of current practice (referred to as the
standard invitation). Randomization of individuals by
household clusters is undertaken from a central site fol-
lowing stratification by cluster size and general practice.
The trial is set in four general practices and participants are
recruited from practice lists. The informed choice invita-
tion is designed to be replicable in a primary care setting
using minimal resources. The design protects the primary
end point by measuring attendance before providing fur-
ther information about the trial or collecting question-
naire data that may have intervention effects. The trial is
managed jointly between Kings College London and the
University of Cambridge. COREC approval has been
given (REC: Cambridgeshire 1: 06/Q0104/17, 05th May,
2006), and R&D approval has been obtained from Greater
Peterborough PCP, and Suffolk West PCT.
Practice recruitment
The study is conducted in four general practices recruited
from Cambridgeshire and surrounding counties, including
two with above average area deprivation scores (in or above
the middle quintile of the Index of Multiple Deprivation
2004). The practices are selected using a combination of
information on practice participation in the Wellcome
funded ADDITION trial (ISRCTN86769081), deprivation
scores, and local interest in participation in research.
14 practices are selected for initial contact by letter, to
invite participation and request a meeting between the
practice team and the research team. At this meeting,
research and clinical procedures are outlined, and mem-
bers of the practice team are provided with a written sum-
mary of the study and a Research Information Sheet for
Practices [52]. Before making a decision they are asked to
discuss the study with the rest of the practice team and
inform the trial co-ordinator of their decision within one
month. Four study practices and two reserve practices are
needed to ensure a sufficient sample size.
Participant recruitment
The sample is selected from practice registers. It includes
participants without known diabetes and in the top 25% of
risk of having prevalent undiagnosed diabetes defined by a
validated risk score. The Cambridge Risk Score [42] has
been validated as a pre-screening instrument for the identi-
fication of those at increased risk of having prevalent undi-
agnosed diabetes [42,49-51,53]. For example, Griffin and
colleagues [42] reported an area of 80% under a receiver-
operating characteristic curve. Risk scores are obtained
from a MIQUEST READ code based search of routinely-
held practice data (weight, height, BMI, age, gender, antihy-
pertensive and steroid medication). Risk scores have been
calculated for over 150,000 people in practices in Cam-
bridgeshire and surrounding counties participating in the
ADDITION trial [54]. It is estimated that sufficient practice
data are recorded to enable risk score calculations to be
undertaken for around 70% of patients.
Exclusion criteria
Patients meeting the following criteria are excluded from
the trial:
i. Diagnosed with diabetes since the medical record search
was performed.
ii. Pregnant or breast-feeding.
iii. Have a psychotic illness, such as schizophrenia, hypo-
mania, major depression, manic depression.
iv. Have an illness with a likely prognosis of less than one
year to death.
Consent process
Potential participants are sent a letter from the practice
with which they are registered informing them that the
practice is going to undertake screening for diabetes as
part of a research trial, and asking them to opt out if they
do not wish to be invited. Those wishing to opt out are
asked to return a freepost card to the practice.
When individuals attend for screening they are given the
trial "patient information sheet" and then asked for con-
sent to complete two questionnaires and for screening test
results to be seen by researchers. For those who do not
attend, information is given and consent obtained at the
time of sending a questionnaire by post.
Development and evaluation of the intervention materials
Standard invitation
The standard invitation is modeled on invitations com-
monly used to invite people for diabetes and coronary
heart disease screening [11,55]. The text states that the par-
ticipant is being offered screening because they might have
a higher chance of developing type 2 diabetes, and that dia-Page 4 of 12
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Diagram of participant flow through the DICISION trialFigure 1
Diagram of participant flow through the DICISION trial.
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Complete a questionnaire  
Secondary outcome: Intention to change 
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Other outcomes:  SES, worry about 
diabetes, expected results, ZTPI*  
Sent invitation: 
Take a RBG test 
Normal result  
Give health promotion 
information 




Measure CVD risk 
Give written record of 






Within 7 days 
4 weeks later 
2-3 weeks later 
Take FBG test  
Measure height weight, 
BP and lipids  
Send non-attender 
questionnaire
Other outcome:  intention 
to change lifestyle 
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worry about diabetes, 
ZTPI*, decision satisfaction
Send time 2 questionnaire  
Other outcome:  intention to change lifestyle 
Other measures: decision satisfaction, perceived 
impact of results on diabetes status 
Did not attend 
Randomised  
N = 1272 
Excluded                   N = 228 
 - Criteria not met       n = 43 
 - Opted out                 n = 183 
 - Opt out undelivered n = 2 
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eligibility 
N = 1500 
Allocated to receive the 
standard invitation 
N = 639 
Allocated to receive the 
informed choice invitation 
N = 633 
*Zimbarbo Time Perspective Inventory (short form)
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file 1). An appointment date and time is also included, as
well as instructions for rearranging or cancelling the
appointment. The text is designed to be comprehensible to
those with a reading age of 11 or above (Flesch Reading
Ease score was 71.52, Flesch-Kinaid Grade level = 6.34).
Informed choice invitation
The informed choice invitation contains the same infor-
mation as the standard invitation, plus information about
risk of diabetes and its complications, and the likelihood
of individual positive and negative consequences of
attending for screening (see additional file 2). Participants
are encouraged to make a choice that reflects their values
by prompting evaluation of consequences, and asking
them to record their decision to attend or not. Flesch
Reading Ease score = 72.88 and Flesch-Kinaid Grade level
= 5.76, indicating that the invitation should be readable
by those with a reading age of 11 or above. Study materi-
als and documents described in this protocol are available
from the corresponding author on request.
Providing information about diabetes risk and consequences of 
screening
This section is developed from the UK General Medical
Council (GMC) guidelines for providing sufficient infor-
mation when gaining patient consent [56]. The invitation
begins with an emphasis on patient choice; "Screening for
diabetes. It's your decision", and is followed by the informa-
tion given in the standard invitation. An invitation to
think about possible benefits and harms before deciding
whether to attend is then followed by an explanation of
diabetes and the screening procedure. This is followed by
an explanation of the different possible results and their
meaning. An outline of how diabetes is treated with life-
style change and pills is presented, followed by a presen-
tation of the size of the possible individual benefits and
harms of attending for screening and participating in
treatment for diabetes were it to be subsequently diag-
nosed. All this information is given in words, numbers
and graphically displayed using pie charts.
Encouraging participants to make a value consistent choice
A decisional balance sheet [57] is used to facilitate value-
action consistency. It comprises an instruction to partici-
pants to write down the positive and negative conse-
quences of attending diabetes screening for them,
followed by their decision as to whether to attend their
appointment or not, or to think more about whether or
not they want to go for screening.
Validation of the informed choice invitation
A randomized controlled analogue study was conducted
among a volunteer sample of the general public in order
to establish whether this invitation results in higher rates
of informed choice than the standard invitation.
Informed choice was assessed using a multidimensional
measure of informed choice [27], which defines such
choice as a behavior consistent with values in the context
of appropriate knowledge [26,27].
Levels of informed choice were significantly higher fol-
lowing receipt of an informed choice invitation compared
to the standard invitation; immediately after receipt
(49.6% versus 7.2%; difference = 42.5% (95% CI: 33.7%
to 50.3%); χ2 = 72.922(1), p < 0.001) and two weeks later
(42.9% versus 11.2%; difference = 31.7% (95% CI: 22.5%
to 40.5%); χ2 = 41.121(1), p < 0.001). This effect reflected
increased knowledge of the benefits and costs of screening
which was low, but not changes in attitude or intention to
attend for screening which were highly positive [58].
Procedure
Recruitment and randomization
Each of the four practices run the MIQUEST READ search
program on the practice medical records and supply the
trial statistician with the results for patients with diabetes
risk scores in the top quartile. Each patient is assigned an
ID number and 350 are randomly selected (450 from the
final practice). Practice staff check patients' medical
records to exclude any patients meeting the exclusion cri-
teria outlined above. The remaining patients are sent the
letter informing them of the trial and giving them an
opportunity to opt out of receiving an invitation.
Returned opt out forms are collated by a member of prac-
tice staff, and the trial statistician is informed of the IDs of
the excluded and opted out patients.
The estimated 1200 individuals remaining after exclusions
and opt-outs are randomized from a central site, stratified
by practice and by cluster size (the number of individuals
eligible for randomization in a household after removing
those choosing to opt-out or excluded by the practice). This
ensures that all eligible individuals in a household are co-
selected and co-randomized to the same arm.
Selection and randomization is performed by the trial
statistician with access only to data needed to calculate the
risk score and to stratify the randomization, and is inde-
pendent of the trial co-ordination team and database.
Randomized participants are sent either an informed
choice invitation or a standard invitation to a screening
clinic conducted by a DICISION research nurse, taking
place at the patients' practice. Letters are sent from the
practice, and appointments are pre-assigned. Participants
can contact the practice as normal to rearrange or cancel
their appointments.
Data collection
Attendance is recorded by a research nurse upon the par-
ticipant's arrival. The participant then reads a patientPage 6 of 12
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study and written consent is obtained from the partici-
pant. Where consent is refused, participants retain the
opportunity to take the screening test if they wish. Where
consent is obtained, participants then complete a ques-
tionnaire containing the measures shown in table 1.
The nurse then explains the screening procedure and car-
ries out a finger prick random capillary blood glucose
(RBG) test using HemoCue B-glucose analyzer based on
the glucose dehydrogenase reaction (HemoCue AB,
Angelholm, Sweden). The stability of the analyses is
checked daily and an external calibration with the quality
assurance scheme is undertaken monthly. Participants
with a RBG level of less than 5.5 mmol/L are given stand-
ardized basic lifestyle advice on health eating and exercise.
Those with RBG level equal to or greater than 5.5 mmol/
L are invited to return for a fasting blood glucose test, car-
ried out by the research nurse. Where blood glucose is
over 22 mmol/L the participant is referred to the practice
for review that day.
The subsequent fasting blood glucose (FBG) appointment
is offered as a necessary clinical duty of care to the partic-
ipant. A finger prick blood test is conducted to measure
fasting capillary blood glucose level and a full lipid pro-
file. Height, weight, blood pressure and cardiovascular
risk score ([59]; the Cardiac Risk Assessor software is avail-
able from Prof Paul Durrington, University of Manches-
ter) are also measured. Patients are offered further
standardized lifestyle advice. Those with FBG levels equal
to or greater than 6.1 mmol/L are referred to the practice
for diagnostic testing.
Four weeks after the RBG appointment, consenting
attenders are sent a follow up questionnaire containing
the measures listed in table 1. Questionnaires are returned
to the trial co-ordinator.
If a person cancels or misses their appointment, their non-
attendance is recorded and a member of the practice team
sends a non-attender pack to the patient, consisting of a
questionnaire, a patient information sheet, consent form
and reply-paid envelope. If no response is received within
3 weeks, then a reminder letter and another non-attender
pack is sent. Measures contained in the non-attender ques-
tionnaire are shown in table 1. As practices are responsible
for the administration of appointments, occasionally a par-
ticipant who misses their appointment without informing
the practice (classified as a non-attender) may subsequently
rearrange and attend another appointment (therefore
change to attender status). These participants are included
Table 1: Study measures
Measures From practice records At appointment, but before 
RBG test
4 weeks after appointment If appointment not attended
Attendance X
Questionnaire measures
Intention to change lifestyle 
if found to have diabetes 
(Intention 1)*
X
Intention to change lifestyle 
(Intention 2)
X X
Worry about getting 
diabetes [63]
X X
Expected test results* X
Time Orientation (ZTPI – 
Short form [64])
X X
Age, gender, ethnic group X X
Social deprivation 
indicators: qualifications, 
home and car ownership
X X
Decision satisfaction [61] X X




Postcode (to identify IMD 
2007 score [60])
X





* Attenders onlyPage 7 of 12
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possible that the non-attender questionnaire prompts
attendance in this case, rather than the invitation. We do
not expect this to occur frequently, or to vary by trial arm.
We will, however, record the number of attenders who are
sent a non-attender questionnaire, and supplementary
analyses excluding these participants may be necessary.
Participant safety
Data collection and clinical procedures are detailed in a
written clinical protocol and are managed by a grade H
research nurse. Research nurses have up to date Hepatitis
B vaccination, are certified in providing Basic Life Sup-
port, and follow the joint Addenbrooke's and University
of Cambridge policy for managing exposure to blood.
Procedures for dealing with medical emergencies are fol-
lowed when necessary.
Adverse events monitoring
A detailed adverse events protocol has been produced for
the research nurses by the clinical coordinator (SPS),
including potential adverse events, their management and
reporting procedures. The definition of adverse events
excludes abnormal study outcome results, which are dealt
with in the clinical protocol. All adverse events are
reported to the trial coordinator and to the principal
investigator. A signed and dated report is logged in the
Trial Management File. Any adverse event deemed to be a
serious adverse event after consultation with the principal
investigators is reported to the University and NHS ethics
committees within 24 hours.
Main trial outcomes and measures
Attendance (primary outcome)
The primary outcome among those randomized to receive
an invitation to screening is attendance for diabetes
screening as a proportion of those randomized. Attend-
ance is defined as arrival at an appointment, regardless of
subsequent participation or previous missed appoint-
ments. All other randomized participants are defined as
non-attenders.
Social deprivation
The primary measure of social deprivation is the Index of
Multiple Deprivation 2007 (IMD 2007[60]). The IMD
2007 is published by the UK Department for Communi-
ties and Local Government. Geographical areas (approxi-
mate population 1500 per area) are rated on seven
indicators of deprivation: i) income, ii) employment, iii)
health, deprivation & disability, iv) education, skills and
training, v) barriers to housing and services, vi) crime, and
vii) living environment. The scores are weighted, summed
and transformed resulting in a score from 0–100 where an
average score of above 50 represents the 10% most
deprived areas in the UK. Patient postcodes are used to
identify a deprivation score for where they live.
Attenders' intention to make lifestyle changes if found to have 
diabetes (secondary outcome; intention 1)
The secondary outcome among those attending for
screening is intention to make lifestyle changes if subse-
quent tests were to show that they had diabetes. This
measure is a behavioral expectation in response to a hypo-
thetical scenario, measured at the screening appointment
with a self completed questionnaire, prior to taking the
diabetes test. It is the mean of three intention items relat-
ing to medication adherence, reducing fat intake and
increasing physical activity. Items are rated on a 7 point
rating scale. An example of one of the items is: "If the tests
show that you definitely do have diabetes, how likely is it
that you will increase the amount of physical activity that
you do over the next 3 months" (1 = extremely unlikely –
7 = extremely likely).
Decision satisfaction
This is measured in the four-week follow up questionnaire
sent to attenders. A three item measure assesses the extent
to which the choice is considered to be a good one, satis-
faction with the way in which the decision was made, and
certainty that the decision made was the best one for them
e.g. "How sure are you that the decision you made was the
right one for you?" (1 = not at all – 7 = extremely). In an
earlier study this was found to have good reliability [61].
Supplementary trial outcomes and measures
Six other measures were assessed:
Intention to make lifestyle changes (intention 2)
Attenders' and non-attenders' intentions to make lifestyle
changes are assessed in the four-week follow up question-
naire for attenders, and in the non-attenders' question-
naire. This measure is a behavioral expectation of actual
lifestyle change and is structured in the same way as the
item described above, as Intention 1.
Multiple individual-level social deprivation index
A secondary measure of individually defined social depri-
vation is used in supplementary analyses of participants
who respond to questionnaires. A 5-point scale giving
scores ranging from zero to four is calculated from self
reported demographic information [62]. A participant
scores one point for each of the following criteria that
apply to them: a) do not own a car, b) do not own their
own home, c) do not have post-16 level educational qual-
ifications, and d) do not have any educational qualifica-
tions.
Additional self report measures
Additional self report measures include worry about get-
ting diabetes [63], present and future orientation, using a
short form of the Zimbardo Time Perspective Inventory
(ZTPI [64]), and for attenders only, expected results and
perceived impact of results on diabetes status. Descrip-Page 8 of 12
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measurement are summarized in table 1.
Power
A sample size of 1200 participants ensures 90% power to
detect a 10% difference in attendance between arms using
a comparison between proportions with a chi-squared test
at the 5% significance level. With a predicted average
attendance of 65% [11], 780 attenders are expected.
Responses from all 780 attenders to the initial question-
naire provides 80% power to detect a small effect size (0.2
sd standardized difference) between arms in the primary
intention measure using a t-test at the 5% level of signifi-
cance. Allowing for a 75% response rate at the second
time-point amongst attenders, there is 80% power to
detect 0.25 sd effect size between arms for the continuous
measures of intention and decision satisfaction. Assuming
a small mean cluster size of 1.2 participants per rand-
omized household and a conservatively high intracluster
correlation of 0.8, secondary analyses allowing for cluster-
ing maintain 90% power to detect a 10% difference in
attendance and 80% power to detect a 0.25 sd effect size
amongst attenders.
Statistical analysis
The chi-squared test is used to compare intention to treat
attendance and other proportions between arms. The t-
test is used to compare means of attenders' intention and
other continuous measures between arms. Linear and
logistic regressions are used to assess moderators using
interaction terms where moderator variables are main-
tained as continuous. All analyses are two-tailed and
assessed at the 5% level of significance. For statistically
significant analyses, Donner's z-test for proportions and
the linear mixed effects model for continuous outcomes
are used in secondary sensitivity analysis accounting for
clustering, assessing whether randomization by house-
hold affects the conclusions.
Discussion
DICISION is a rigorously designed pragmatic population
based clinical trial of an invitation to type 2 diabetes
screening, designed to facilitate informed choice. The trial
tests the hypotheses that knowledge of the uncertain per-
sonal benefits and potential harms of diabetes screening
results in lower attendance, but amongst those attending,
a higher likelihood of changing behavior to reduce com-
plications of diabetes, were it to be subsequently diag-
nosed. We are also testing the hypothesis that facilitating
informed choice reduces diabetes screening attendance to
a greater extent in those who are socially deprived. Due to
report in January 2009, this trial will provide a robust esti-
mate of the impact of a policy of facilitating patient
informed choice in diabetes screening in a primary care
setting.
The trial design is pragmatic in that it closely reflects a
screening programme in primary care up until attendance
is measured, ensuring that the primary outcome cannot
be influenced by prior measurement. Participants are
selected from practice registers on the basis of routine data
signifying increased risk of diabetes. Invitation letters are
sent from participants' GPs and screening takes place at
the surgery. An opt-out method of seeking consent to
measure attendance is used. An opt-in method of consent
to participate in the remainder of the trial is used after the
primary outcome is measured. Providing significant infor-
mation before attendance could affect the decision to
attend, particularly in the comparison group, and so
diminish the effect of the informed choice invitation [35].
Using the same procedure for obtaining consent in
another screening study resulted in 4% opting out [65],
suggesting that external validity is not compromised by
adopting this method of consent.
The primary outcome is objectively measured; all partici-
pants can be identified as either an attender or a non-
attender. Questionnaire data are collected after the pri-
mary outcome is recorded as evidence suggests that ques-
tionnaires may alter research outcomes [36-38]. In
addition, the questionnaires are brief to maximize
response rates.
An evidence-based invitation was developed from GMC
guidelines [56] to provide up-to-date information about
diabetes screening. Invitation text and layout were devel-
oped using evidence-based risk communication recom-
mendations [66]. The effectiveness of the intervention
was tested in a randomized controlled analogue study.
The results showed that the informed choice invitation
compared with a standard invitation was effective at
achieving higher rates of informed choice, due largely to
its increasing knowledge [58].
This is the first trial, to our knowledge, assessing the
impact of facilitating informed choices for screening that
uses a validated informed choice invitation and objec-
tively measures screening uptake, whilst controlling for
the methodological biases described above. As a result it
is not always clear whether differences in findings
between studies relate to the characteristics of the disease
screened for, or to differences in trial methods. Screening
programmes differ in the precision and invasiveness of
the test offered, as well as the prevalence, severity and
treatability of the disease for which screened is being
offered. For example the potential harms of diabetes are
less tangible than those for prostate cancer screening, for
which treatment can lead to incontinence or impotence
[67]. Trials of decision aids for prostate cancer screening
tend to show lower uptake following the use of decision
aids aimed at facilitating informed choices [32,68-70]Page 9 of 12
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colorectal screening, prenatal diagnosis and breast cancer
screening more often found no difference in screening
intention or uptake [29].
There are drawbacks to validating the intervention in an
analogue study and evaluating its impact in a clinical trial.
For example, in the analogue study all participants were
observed to read their invitations, whereas in the clinical
trial we can only be certain that participants are sent invi-
tations. Invitations may not be received or, if received,
may not be read properly. There are also other limitations.
We used an area level index of social deprivation in indi-
viduals. As patients from the same practice live in geo-
graphically similar areas, an area level index is likely to
have less variation than an individual level measure. It is
used, however, to enable an intention to treat analysis of
moderator effects on uptake. Nonetheless, this trial
addresses some key limitations of previous trials through
using previously validated invitations and an opt-out con-
sent procedure in a real world setting.
The generalizability of the findings from this trial to other
screening programmes is unknown. The harms that can
arise from screening for diabetes are generally not consid-
ered serious and are described in the invitations as com-
prising worry prior to an appointment and false
reassurance following a "screen negative" test result. In
contrast, undergoing other screening tests can entail phys-
ical harms that include disability and even death e.g.
colonoscopy [72]. Evidence of the impact of knowledge
about such potential harms and the uncertain limited
individual benefit of screening is mixed [29,73]. The
extent to which the results of the current trial can be
extrapolated to these other contexts will await results from
similar trials to the one described in this protocol.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
TMM, ALK, SG, ATP, SS, MP are Principal Investigators;
ATP is the trial statistician; EM is the trial coordinator; IK
is the Pilot Study coordinator and contributed to protocol
development; SPS is the clinical coordinator for the trial.
All authors read and approved the final manuscript. TMM
is the paper guarantor.
Additional material
Acknowledgements
We thank Nicola Popplewell, Helen Morris, Kate Williams, Rachel Crock-
ett, Marian Bosman and Fleur Curtis for their contribution to the develop-
ment of the study and the materials. ALK, TMM, SG & SS are members of 
the NIHR School for Primary Care Research. The General Practice and Pri-
mary Care Research Unit is supported by NIHR funds. IK is supported by 
an MRC Co-op Grant.
This study is funded by the Wellcome Trust (Grant no: AL076838, "Didac-
tic versus Informed Choice Invitations: Balancing Public Health Benefits and 
Individual Choice" PI: Theresa Marteau): June 2006 – December 2009.
References
1. Jorgensen K, Gotzsche PC: Content of invitations for publicly
funded screening mammography.  British Medical Journal 2006,
332(7540):538-541.
2. Rose G: Sick individuals and sick populations.  International Jour-
nal of Epidemiology 2001, 30:427-432.
3. National Screening Committee: 2nd Report of the UK National
Screening Committee.  2000.
4. Welch H: Informed choice in cancer screening.  Journal of the
American Medical Association 2001, 285:2776-2778.
5. Marteau T, Kinmonth AL: Screening for cardiovascular disease:
public health imperative or matter for informed choice.  Brit-
ish Medical Journal 2002, 325:78-80.
6. Domenighetti G, Grilli R, Maggi JR: Does provision of an evi-
dence-based information change public willingness to accept
screening tests?  Health Expectations 2000, 3(2):145-150.
7. Edwards A, Elwyn G, Covey J, Matthews E, Pill R: Presenting risk
information – A review of the effects of "framing" and other
manipulations on patient outcomes.  Journal of Health Communi-
cation 2001, 6(1):61-82.
8. Kennedy ADM: On what basis should the effectiveness of deci-
sion aids be judged?  Health Expectations 2003, 6:255-268.
9. Cooke R, French D: How well do the theory of reasoned action
and theory of planned behaviour predict intentions and
attendance at screening programmes? A meta-analysis.  Psy-
chology & Health 2008, 23(7):745-765.
10. Raffle AE: Information about screening – is it to achieve high
uptake or to ensure informed choice?  Health Expectations 2001,
4:92-98.
11. Wood DA, Kinmonth AL, Davies GA, Yarwood J, Thompson SD,
Pyke SDM, Kok Y, Cramb R, Le Guen C, Marteau TM: Randomised
controlled trial evaluating cardiovascular screening and
intervention in general practice: principal results of British
family heart study.  British Medical Journal 1994, 308:313-320.
12. Cockburn J, Redman S, Hill D, Henry E: Public understanding of
medical screening.  Journal of Medical Screening 1995, 2:224.
13. Dobias K, Moyer C, McAchran S, Katz S, Sonnad S: Mammography
messages in popular media: implications of patient expecta-
tions and shared clinical decision-making.  Health Expectations
2001, 4:131-139.
14. Domenighetti G, D'Avanzo B, Egger M, Berrino F, Perneger T,
Mosconi P, Zwahlen M: Women's perception of the benefits of
mammography screening: population-based survey in four
countries.  International Journal of Epidemiology 2003, 32(5):816-821.
15. Crockett RA, Weinman J, Hankins M, Marteau T: Time orientation
and health-related behaviour: Measurement in general pop-
ulation samples.  Psychology & Health  in press.
16. Wardle J, Steptoe A: Socioeconomic differences in attitudes
and beliefs about healthy lifestyles.  Journal of Epidemiology and
Community Health 2003, 57(6):440-443.
Additional file 1
The standard invitation.




The invitation designed to facilitate informed choice.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2458-9-63-S2.pdf]Page 10 of 12
(page number not for citation purposes)
BMC Public Health 2009, 9:63 http://www.biomedcentral.com/1471-2458/9/6317. Schwartz MD, Rimer BK, Daly M, Sands C, Lerman C: A rand-
omized trial of breast cancer risk counseling: the impact on
self-reported mammography use.  American Journal of Public
Health 1999, 89(6):924-926.
18. Cioffi D, Garner R: On Doing the Decision: Effects of Active
versus Passive Choice on Commitment and Self-Perception.
Personality and Social Psychology Bulletin 1996, 22(2):133.
19. Edwards W: Behavioral Decision Theory.  Annual Reviews in Psy-
chology 1961, 12(1):473-498.
20. Ley P: Communicating with patients: improving communication, satisfaction
and compliance Chapman and Hall, London; New York; 1988. 
21. Marteau TM, Weinman J: Communicating about Health
Threats and Treatments.  The SAGE Handbook of Health Psychology
2004:270-298.
22. Ryan RM, Deci EL: Self-determination theory and the facilita-
tion of intrinsic motivation, social development, and well-
being.  American Psychologist 2000, 55(1):68-78.
23. Ryan R, Deci E: Self-Regulation and the Problem of Human
Autonomy: Does Psychology Need Choice, Self-Determina-
tion, and Will?  Journal of Personality 2006, 74(6):1557-1586.
24. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year
follow-up of intensive glucose control in type 2 diabetes.  New
England Journal of Medicine 2008, 359(15):1577-1589.
25. UKPDS Group: Tight blood pressure control and risk of mac-
rovascular and microvascular complications in type 2 diabe-
tes: UKPDS 38.  BMJ 1998, 317:703-713.
26. Bekker H, Thornton JG, Airey CM, Connelly JB, Hewison J, Robinson
MB, Lilleyman J, MacIntosh M, Maule AJ, Michie S: Informed deci-
sion making: an annotated bibliography and systematic
review.  Health Technology Assessment 1999, 3(1):1-156.
27. Marteau TM, Dormandy E, Michie S: A measure of informed
choice.  Health Expectations 2001, 4(2):99-108.
28. O'Neill O: Some limits of informed consent.  Journal of Medical
Ethics 2003, 29(1):4-7.
29. O'Connor A, Stacey D, Entwistle V, Llewellyn-Thomas H, Rovner D,
Holmes-Rovner M, Tait V, Tetroe J, Fiset V, Barry M: Decision aids
for people facing health treatment or screening decisions.
Cochrane database of systematic reviews (Online) 2003:CD001431.
30. Bastian LA, McBride CM, Fish L, Lyna P, Farrell D, Lipkus IM, Rimer
BK, Siegler IC: Evaluating participants' use of a hormone
replacement therapy decision-making intervention.  Patient
Education and Counseling 2002, 48(3):283-291.
31. O'Connor AM: Validation of a Decisional Conflict Scale.  Medi-
cal Decision Making 1995, 15(1):25-30.
32. Krist A, Woolf S, Johnson R, Kerns J: Patient Education on Pros-
tate Cancer Screening and Involvement in Decision Making.
The Annals of Family Medicine 2007, 5(2):112-119.
33. Mathieu E, Barratt A, Davey HM, McGeechan K, Howard K, Hous-
sami N: Informed Choice in Mammography Screening: A Ran-
domized Trial of a Decision Aid for 70-Year-Old Women.
Archives of Internal Medicine 2007, 167(19):2039-2046.
34. Trevena LJ, Irwig L, Barratt A: Randomized trial of a self-admin-
istered decision aid for colorectal cancer screening.  Journal of
Medical Screening 2008, 15(2):76-82.
35. Gallo C, Perrone F, De Placido S, Giusti C: Informed versus ran-
domised consent to clinical trials.  Lancet 1995,
346(8982):1060-1064.
36. Kinmonth AL, Wareham NJ, Hardeman W, Sutton S, Prevost AT,
Fanshawe T, Williams KM, Ekelund U, Spiegelhalter D, Griffin SJ: Effi-
cacy of a theory-based behavioural intervention to increase
physical activity in an at-risk group in primary care (ProAc-
tive UK): a randomised trial.  Lancet 2008, 371(9606):41-48.
37. Ogden J: Some problems with social cognition models: A
pragmatic and conceptual analysis.  Health Psychology 2003,
22(4):424-428.
38. van Sluijs EMF, van Poppel MNM, Twisk JWR, van Mechelen W: Phys-
ical activity measurements affected participants' behavior in
a randomized controlled trial.  Journal of Clinical Epidemiology
2006, 59(4):404-411.
39. Kohro T, Furui Y, Mitsutake N, Fujii R, Morita H, Oku S, Ohe K, Nagai
R: The Japanese national health screening and intervention
program aimed at preventing worsening of the metabolic
syndrome.  International Heart Journal 2008, 49(2):193-203.
40. National Screening Committee: Handbook for Vascular Risk
Assessment, Risk Reduction and Risk Management.  Univer-
sity of Leicester; 2008. 
41. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton
S: Putting prevention first.  In Vascular checks: risk assessment and
management London: Central Office of Information; 2007. 
42. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ: Diabetes
risk score: towards earlier detection of Type 2 diabetes in
general practice.  Diabetes/Metabolism Research and Reviews 2000,
16(3):164-171.
43. Wareham NJ, Griffin SJ: Should we screen for type 2 diabetes?
Evaluation against National Screening Committee.  British
Medical Journal 2001, 322:986-988.
44. Adriaanse CA, Snoek FJ: The psychological impact of screening
for type 2 diabetes.  Diabetes/Metabolism Research and Reviews
2006, 22(1):20-25.
45. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton
S: Psychological impact of screening for type 2 diabetes: con-
trolled trial and comparative study embedded in the ADDI-
TION (Cambridge) randomised controlled trial.  British
Medical Journal 2007, 335(7618):486-489.
46. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT,
Davies MJ, Khunti K: Different strategies for screening and pre-
vention of type 2 diabetes in adults: cost effectiveness analy-
sis.  British Medical Journal 2008, 336(7654):1180-1185.
47. Glümer C, Yuyun M, Griffin S, Farewell D, Spiegelhalter D, Kinmonth
AL, Wareham NJ: What determines the cost-effectiveness of
diabetes screening?  Diabetologia 2006, 49(7):1536-1544.
48. Goyder EC: Screening for and prevention of type 2 diabetes.
British Medical Journal 2008, 336(7654):1140-1141.
49. Heldgaard PE, Griffin SJ: Routinely collected general practice
data aids identification of people with hyperglycaemia and
metabolic syndrome.  Diabetic Medicine 2006, 23(9):996-1002.
50. Park PJ, Griffin SJ, Sargeant L, Wareham NJ: The Performance of a
Risk Score in Predicting Undiagnosed Hyperglycemia.  Diabe-
tes Care 2002, 25(6):984-988.
51. A simple risk score identifies individuals at high risk of devel-
oping Type 2 diabetes: a prospective cohort study.  .
52. Bateman H: A Research Information Sheet for Practices
(RISP): a tool to facilitate research participation.  Volume 19.
Oxford Univ Press; 2002:691-697. 
53. Spijkerman A, Yuyun M, Griffin S, Dekker J, Nijpels G, Wareham N:
The Performance of a Risk Score as a Screening Test for
Undiagnosed Hyperglycemia in Ethnic Minority Groups:
Data from the 1999 Health Survey for England.  Diabetes Care
2004, 27(1):116-122.
54. Echouffo-Tcheugui JB, Sargeant LA, Prevost AT, Williams KM, Barling
RS, Butler R, Fanshawe T, Kinmonth AL, Wareham NJ, Griffin SJ:
How much might cardiovascular disease risk be reduced by
intensive therapy in people with screen-detected diabetes?
Diabetic Medicine 2008, 25:1433-9.
55. Muir J, Mant D, Jones L, Yudkin P, on behalf of the Imperial Cancer
Research Fund OXCHECK study group: Effectiveness of health
checks conducted by nurses in primary care: Results of the
OXCHECK study after one year.  British Medical Journal 1994,
308:308-312.
56. General Medical Council: Seeking Patients' Consent: The Ethical Consid-
erations London: GMC; 1998. 
57. Wankel LM, Yardley JK, Graham J: The effects of motivational
interventions upon the exercise adherence of high and low
self-motivated adults.  Can J Appl Sport Sci 1985, 10(3):147-156.
58. Kellar I, Sutton S, Griffin S, Prevost AT, Kinmonth AL, Marteau TM:
Evaluation of an informed choice invitation for type 2 diabe-
tes screening.  Patient Education and Counseling 2008, 72:232-238.
59. British Cardiac Society, British Hypertension Society, Diabetes UK,
HEART UK, Primary Care Cardiovascular Society, The Stroke Asso-
ciation: Joint British Societies' guidelines on prevention of
cardiovascular disease in clinical practice.  Heart 2005,
91(Suppl V):v1-v52.
60. Noble M, McLennan D, Wilkinson K, Whitworth A, Barnes H, Dibben
C: The English Indices of Multiple Deprivation 2007.  London
2008.
61. Michie S, McDonald V, Marteau TM: Genetic Counselling: Infor-
mation Given, Recall and Satisfaction.  Patient Education and
Counseling 1997, 32:101-106.
62. Sutton S, Gilbert H: Effectiveness of individually tailored smok-
ing cessation advice letters as an adjunct to telephone coun-
selling and generic self-help materials: randomized
controlled trial.  Addiction 2007, 102(6):994-1000.Page 11 of 12
(page number not for citation purposes)
BMC Public Health 2009, 9:63 http://www.biomedcentral.com/1471-2458/9/63Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
63. Cameron LD, Reeve J: Risk perceptions, worry, and attitudes
about genetic testing for breast cancer susceptibility.  Psychol-
ogy & Health 2006, 21(2):211-230.
64. Zimbardo G, Boyd N: Putting time in perspective: a model reli-
able individual-difference metric.  Journal of Personality and Social
Psychology 1999, 72(6):1271-1288.
65. French DP, Maissi E, Marteau TM: Psychological costs of inade-
quate cervical smear test results.  British Journal of Cancer 2004,
91:1887-1892.
66. Gigerenzer G, Edwards A: Simple tools for understanding risks:
from innumeracy to insight.  British Medical Journal 2003,
327(7417):741.
67. Frankel S, Smith G, Donovan J, Neal D: Screening for prostate
cancer.  The Lancet 2003, 361(9363):1122-1128.
68. Gattellari M, Ward J: Does evidence-based information about
screening for prostate cancer enhance consumer decision-
making? A randomised controlled trial.  J Med Screen 2003,
10(1):27-39.
69. Frosch D, Kaplan R, Felitti V: A Randomized Controlled Trial
Comparing Internet and Video to Facilitate Patient Educa-
tion for Men Considering the Prostate Specific Antigen Test.
Journal of General Internal Medicine 2003, 18(10):781-787.
70. Volk R, Spann S, Cass A, Hawley S: Patient Education for
Informed Decision Making About Prostate Cancer Screen-
ing: A Randomized Controlled Trial with 1-Year Follow-Up.
Annals Family Med; 2003, 1:22-28.
71. Taylor K, Davis J III, Turner R, Johnson L, Schwartz M, Kerner J, Leak
C: Educating African American Men about the Prostate Can-
cer Screening Dilemma: A Randomized Intervention.  Cancer
Epidemiology, Biomarkers & Prevention 2006, 15(11):2179.
72. Garbay J, Suc B, Rotman N, Fourtanier G, Escat J: Multicentre study
of surgical complications of colonoscopy.  British Journal of Sur-
gery 1996, 83(1):42-44.
73. Fox R: Informed choice in screening programmes: do leaflets
help? A critical literature review.  Journal of Public Health 2006,
28(4):309-317.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2458/9/63/prepubPage 12 of 12
(page number not for citation purposes)
